Crescent Biopharma Insider Trades
NASDAQ: CBIOHealth CareBiotechnology: Pharmaceutical PreparationsUSD
14.91+0.79 (+5.59%)
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Last 12 months
- Purchases
- 2 · $30.61M
- Sales
- 16 · $1.51M
- Shares bought / sold
- 2.21M / 84.88K
- Net activity
- Net buying $29.1 million
Crescent Biopharma insider activity
Over the last 12 months, Crescent Biopharma insiders reported 34 transactions on SEC Form 4: 2 open-market purchases and 16 sales. Insiders bought $30.6 million and sold $1.5 million worth of stock, for net insider buying of $29.1 million. The largest seller was Brumm Joshua T, with $920,842 in reported sales.
The most recent filing shows Brumm Joshua T (Chief Executive Officer) selling 7,837 shares at $16.71 on Sep 18, 2026. Insider sales are common for compensation, tax and diversification reasons, while open-market purchases are rarer; tracking both helps put CBIO's ownership changes in context.
Summary generated from market data by MetaCap's automated system. Methodology
CBIO insider transactions
| Date | Insider | Type | Shares | Value | Filing |
|---|---|---|---|---|---|
| Sep 18, 2026 | McNeill JonathanPresident and COO | Sale | 3,839 | $64.15K | Form 4 |
| Sep 18, 2026 | Brumm Joshua TChief Executive Officer | Sale | 7,837 | $130.96K | Form 4 |
| Sep 16, 2026 | McNeill JonathanPresident and COO | Sale | 731 | $13.08K | Form 4 |
| Sep 16, 2026 | Brumm Joshua TChief Executive Officer | Sale | 1,610 | $28.82K | Form 4 |
| Sep 16, 2026 | Scalzo Richard WilliamChief Financial Officer | Sale | 568 | $10.17K | Form 4 |
| Sep 16, 2026 | Pinkas JanChief Scientific Officer | Sale | 658 | $11.78K | Form 4 |
| Sep 16, 2026 | Lynch RyanSee Remarks | Sale | 240 | $4.30K | Form 4 |
| Sep 16, 2026 | Bispham Barbara HarlinSee Remarks | Sale | 620 | $11.10K | Form 4 |
| Sep 16, 2026 | Im Ellie EunkyungChief Medical Officer | Sale | 623 | $11.15K | Form 4 |
| Jul 16, 2026 | Fairmount Funds Management LLC & Fairmount Healthcare Fund II L.P. & Kiselak Tomas & Harwin Peter EvanDirector | Buy | 853,450 | $12.38M | Form 4 |
| Jun 22, 2026 | Brumm Joshua TChief Executive Officer | Sale | 42,305 | $761.07K | Form 4 |
| Jun 22, 2026 | McNeill JonathanPresident and COO | Sale | 20,549 | $369.68K | Form 4 |
| Jun 22, 2026 | Im Ellie EunkyungChief Medical Officer | Sale | 1,219 | $21.93K | Form 4 |
| Jun 22, 2026 | Bispham Barbara HarlinSee Remarks | Sale | 1,218 | $21.91K | Form 4 |
| Jun 22, 2026 | Scalzo Richard WilliamChief Financial Officer | Sale | 1,112 | $20.00K | Form 4 |
| Jun 22, 2026 | Pinkas JanChief Scientific Officer | Sale | 1,288 | $23.17K | Form 4 |
| Jun 22, 2026 | Lynch RyanSee Remarks | Sale | 465 | $8.37K | Form 4 |
| Dec 15, 2025 | Im Ellie EunkyungChief Medical Officer | Award | 5,000 | — | Form 4 |
| Dec 15, 2025 | Im Ellie EunkyungChief Medical Officer | Award | 16,298 | — | Form 4 |
| Dec 15, 2025 | Scalzo Richard WilliamChief Financial Officer | Award | 5,000 | — | Form 4 |
| Dec 15, 2025 | Scalzo Richard WilliamChief Financial Officer | Award | 14,422 | — | Form 4 |
| Dec 15, 2025 | Bispham Barbara HarlinSee Remarks | Award | 6,000 | — | Form 4 |
| Dec 15, 2025 | Bispham Barbara HarlinSee Remarks | Award | 12,422 | — | Form 4 |
| Dec 15, 2025 | Lynch RyanSee Remarks | Award | 4,000 | — | Form 4 |
| Dec 15, 2025 | Lynch RyanSee Remarks | Award | 8,378 | — | Form 4 |
| Dec 15, 2025 | Brumm Joshua TChief Executive Officer | Award | 10,000 | — | Form 4 |
| Dec 15, 2025 | Brumm Joshua TChief Executive Officer | Award | 45,117 | — | Form 4 |
| Dec 15, 2025 | Pinkas JanChief Scientific Officer | Award | 5,000 | — | Form 4 |
| Dec 15, 2025 | Pinkas JanChief Scientific Officer | Award | 17,507 | — | Form 4 |
| Dec 15, 2025 | McNeill JonathanPresident and COO | Award | 6,000 | — | Form 4 |
| Dec 15, 2025 | McNeill JonathanPresident and COO | Award | 19,507 | — | Form 4 |
| Dec 15, 2025 | Doughty Christopher GrantChief Business Officer | Award | 8,000 | — | Form 4 |
| Dec 15, 2025 | Doughty Christopher GrantChief Business Officer | Award | 14,714 | — | Form 4 |
| Dec 4, 2025 | Fairmount Funds Management LLC & Fairmount Healthcare Fund II L.P. & Kiselak Tomas & Harwin Peter EvanDirector | Buy | 1,360,000 | $18.24M | Form 4 |
| Jun 13, 2025 | BVF PARTNERS L P/IL & BIOTECHNOLOGY VALUE FUND L P & BVF I GP LLC & BIOTECHNOLOGY VALUE FUND II LP & BVF II GP LLC & Biotechnology Value Trading Fund OS LP & BVF Partners OS Ltd. & BVF GP HOLDINGS LLC & BVF INC/IL & LAMPERT MARK N10% Owner | other | 56,079 | — | Form 4 |
| Jun 13, 2025 | BVF PARTNERS L P/IL & BIOTECHNOLOGY VALUE FUND L P & BVF I GP LLC & BIOTECHNOLOGY VALUE FUND II LP & BVF II GP LLC & Biotechnology Value Trading Fund OS LP & BVF Partners OS Ltd. & BVF GP HOLDINGS LLC & BVF INC/IL & LAMPERT MARK N10% Owner | other | 556,617 | — | Form 4 |
| Jun 13, 2025 | BVF PARTNERS L P/IL & BIOTECHNOLOGY VALUE FUND L P & BVF I GP LLC & BIOTECHNOLOGY VALUE FUND II LP & BVF II GP LLC & Biotechnology Value Trading Fund OS LP & BVF Partners OS Ltd. & BVF GP HOLDINGS LLC & BVF INC/IL & LAMPERT MARK N10% Owner | other | 657,308 | — | Form 4 |
| Aug 8, 2024 | Invus Public Equities, L.P. & Invus Public Equities Advisors, LLC & Siren, L.L.C. & Invus Global Management, LLC & DEBBANE RAYMOND10% Owner | Sale | 260,873 | $50.01K | Form 4 |
| Aug 7, 2024 | Invus Public Equities, L.P. & Invus Public Equities Advisors, LLC & Siren, L.L.C. & Invus Global Management, LLC & DEBBANE RAYMOND10% Owner | Sale | 61,488 | $11.20K | Form 4 |
| Aug 6, 2024 | Invus Public Equities, L.P. & Invus Public Equities Advisors, LLC & Siren, L.L.C. & Invus Global Management, LLC & DEBBANE RAYMOND10% Owner | Sale | 55,732 | $10.19K | Form 4 |
| Aug 5, 2024 | Invus Public Equities, L.P. & Invus Public Equities Advisors, LLC & Siren, L.L.C. & Invus Global Management, LLC & DEBBANE RAYMOND10% Owner | Sale | 164,523 | $31.00K | Form 4 |
Transaction codes follow SEC Form 4: P = open-market purchase, S = open-market sale, A = grant or award, M = option exercise, F = shares withheld for taxes. About Form 4